NBI-5788 Neurocrine.
Neurocrine Biosciences is developing NBI-5788, an analog of an immunodominant epitope of myelin basic protein for the potential intravenous treatment of multiple sclerosis. By April 2005, enrollment for phase II trials was complete, with results expected early in 2006.
Darlington
Cynthia L
CL
Department of Pharmacology and Toxicology, School of Medical Sciences, University of Otago Medical School, Dunedin, New Zealand. cynthia.darlington@stonebow.otago.ac.nz
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy; D004676:Myelin Basic Protein / Q000276:immunology / Q000627:therapeutic use*; D018377:Neurotransmitter Agents / Q000276:immunology / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use*
D004676:Myelin Basic Protein; D018377:Neurotransmitter Agents; D010446:Peptide Fragments; C415588:NBI 5788